The rationale behind the design lies in one of the most stubborn problems in modern cancer imaging and treatment: heterogeneity. Tumors are not uniform masses of malignant cells but complex ecosystems in which cancer cells are interwoven with stromal cells, immune infiltrates, and a remodeled extracellular matrix. Cancer-associated fibroblasts, which are abundant in many solid tumors and can be identified by their expression of fibroblast activation protein, have become a favored target for theranostic agents because they are present across a wide range of tumor types. At the same time, integrin αvβ3, a receptor that promotes angiogenesis and metastatic behavior, is overexpressed on both certain tumor cells and activated endothelial cells within the tumor vasculature. By targeting both markers with a single molecule, the researchers aimed to increase the fraction of injected radioactivity that reaches and stays within the tumor, rather than relying on a single receptor whose expression may vary widely from patient to patient or even from lesion to lesion within the same patient.

The team, led by researchers from Nanchang University, Southern Medical University, and Harbin Medical University Cancer Hospital, synthesized a series of three candidate compounds, INN01 through INN03, by conjugating a potent boronic acid-based FAP inhibitor motif to either RGDyK or RGDfK cyclic peptides through a DOTA chelator capable of holding both gallium-68 and lutetium-177. In vitro binding assays using A549 cells engineered to express FAP showed that all three heterodimers retained nanomolar affinity for FAP, with IC50 values of 1.28 ± 0.14 nanomolar for INN01, 2.86 ± 0.83 nanomolar for INN02, and 1.07 ± 0.35 nanomolar for INN03. Cellular uptake, internalization, efflux, and blocking experiments performed in U87MG cells, a line known to express integrin αvβ3, allowed the investigators to compare how each construct behaved once bound to its targets and to confirm that uptake could be displaced by excess cold ligand, a hallmark of receptor-specific binding.

When the three candidates were labeled with gallium-68 and tested in mice bearing U87MG tumors, INN02 emerged as the clear frontrunner. Sixty minutes after injection, [68Ga]Ga-INN02 achieved a tumor uptake of 11.65 ± 2.21 percent of the injected activity per gram of tissue, roughly six times higher than the 1.91 ± 1.10 percent measured for [68Ga]Ga-PNT6555, a comparator radiotracer used as a benchmark in the same model. The compound also cleared from the body predominantly through the kidneys, a pharmacokinetic profile that is generally desirable for imaging agents because it limits radiation exposure to the liver and intestines and reduces the likelihood of abdominal background signal that can obscure lesions. Small-animal PET/CT scans confirmed that the high tumor uptake translated into high-contrast images in which tumors stood out clearly against surrounding tissue.

The therapeutic potential of the scaffold was then tested by swapping the imaging isotope for the beta-emitting therapeutic radionuclide lutetium-177. In the same U87MG tumor model, [177Lu]Lu-INN02 reached an early tumor uptake of 21.96 ± 3.09 percent of the injected activity per gram at one hour after injection, compared with 12.98 ± 5.19 percent for [177Lu]Lu-PNT6555, and it showed lower exposure in the liver and blood. Lower off-target accumulation matters enormously in radioligand therapy because the dose that can safely be administered is constrained by the radiation delivered to healthy organs, particularly the kidneys and bone marrow. A probe that concentrates more of its payload in the tumor and less in critical normal tissues can, in principle, deliver a more effective tumoricidal dose within the same safety envelope.

To evaluate efficacy, the researchers treated groups of eight to ten tumor-bearing mice with a single 37-megabecquerel dose of [177Lu]Lu-INN02 and followed tumor growth and survival. By day fourteen, tumors in the treated animals measured 583 ± 338 cubic millimeters on average, compared with 1130 ± 424 cubic millimeters in saline-treated controls, a difference that reached statistical significance with a p-value of 0.030. Median survival was prolonged from sixteen days in the control group to twenty days in the treated group. Importantly, no overt acute toxicity was observed under the conditions tested, although the authors note that the study examined a single-dose regimen and that the safety margins observed in mice will need to be confirmed in larger and longer studies before the compound could advance toward routine clinical use.

The most eye-catching part of the study for clinicians may be the pilot prospective clinical evaluation of [68Ga]Ga-INN02 PET/CT, which enrolled six patients under a trial registered with the Chinese Clinical Trial Registry in March 2022. In these first-in-human images, the tracer demonstrated high uptake in tumor lesions with low background signal across multiple cancer types, allowing clear visualization of both primary tumors and metastatic deposits. Because FAP is expressed by stromal cells rather than by the cancer cells themselves, FAP-targeted imaging has the potential to reveal the full extent of the desmoplastic reaction surrounding a tumor, information that can complement conventional anatomical imaging and other molecular tracers. Adding the integrin αvβ3 component may further broaden sensitivity by flagging tumor cells and newly forming blood vessels that the FAP motif alone would miss.

The theranostic pairing at the heart of the work reflects a broader trend in nuclear medicine, in which the same targeting molecule is labeled with a diagnostic isotope for patient selection and staging and with a therapeutic isotope for treatment, an approach that has already transformed the management of prostate cancer through prostate-specific membrane antigen-targeted radioligand therapy. Gallium-68, with its 68-minute half-life and positron emission, is ideal for same-day PET imaging, while lutetium-177, with a half-life of about 6.7 days and beta emissions that travel a few millimeters in tissue, can irradiate tumor cells while sparing nearby normal tissue. A single precursor molecule that accommodates both isotopes through the same DOTA chelator streamlines manufacturing and regulatory development, because the imaging and therapeutic agents share an identical targeting vector and can be produced from the same chemical intermediate.

The authors are careful to frame the findings as early-stage but encouraging. The clinical component involved only six patients and was designed as a proof-of-concept rather than a definitive assessment of diagnostic accuracy, and the therapy experiments were conducted in a single xenograft model with a single dose level. Heterodimeric constructs also carry inherent design trade-offs: linking two targeting motifs increases molecular size, which can alter pharmacokinetics, and the relative contribution of each receptor to total tumor uptake remains difficult to disentangle without dedicated blocking studies in vivo. Nevertheless, the magnitude of the uptake improvement over the comparator tracer, the favorable renal clearance, and the statistically significant tumor growth inhibition together provide a strong foundation for the further clinical evaluation that the authors say the results support.

If larger studies replicate these findings, dual-target radioligands of this kind could expand the reach of theranostics beyond the tumor types where single-target agents have so far performed best, offering clinicians a way to image and then treat tumors whose stromal and vascular landscapes vary from patient to patient. The work also illustrates how rational molecular design, combining well-validated targeting motifs with established chelation chemistry, can yield compounds that move from bench to first-in-human imaging within a few years. For a field in which the difference between a clear image and a blurry one, or between tumor control and progression, often comes down to how much radioactivity reaches the right cells, INN02’s sixfold advantage in tumor uptake is a result that radiologists, nuclear medicine physicians, and oncologists alike will be watching closely as the compound advances through the clinical pipeline.

Subject of Research: Development of a dual-targeted FAP/integrin αvβ3 heterodimeric radioligand for PET imaging and radionuclide therapy of cancer

Article Title: Design and evaluation of a FAP/αvβ3 dual-targeted 68Ga/177Lu heterodimeric radioligand for cancer theranostics

Article References: Sun, M., Feng, D., Li, X., Chen, B., Li, H., Yang, R., Peng, S., Cheng, L., Zhao, Y., Liu, W., Cao, Q., Wang, K., & Hu, K. (2026). Design and evaluation of a FAP/αvβ3 dual-targeted 68Ga/177Lu heterodimeric radioligand for cancer theranostics. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09034-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09034-9

Keywords: fibroblast activation protein, integrin αvβ3, heterodimeric radioligand, theranostics, PET imaging, lutetium-177, gallium-68, radioligand therapy, tumor microenvironment, cancer-associated fibroblasts, molecular imaging, nuclear medicine

The core logic of the approach is deceptively simple. A target-specific ligand is first labeled with a positron-emitting radionuclide such as gallium-68 or fluorine-18 and used in PET imaging to verify that a patient’s lesions actually express the target and that tracer distributes across the whole body. Only then is a therapeutic radionuclide—commonly lutetium-177, actinium-225, or yttrium-90—attached to the same or a closely related ligand and administered, delivering cytotoxic radiation with relative selectivity to tumor tissue. The authors emphasize that imaging in this context is not an adjunct to therapy but the starting point and foundation of the entire treatment pathway. Target stability, interlesional heterogeneity, physiologic uptake in normal tissues, and the feasibility of dosimetric assessment all directly influence benefit and risk, which is why pretreatment molecular imaging has become an indispensable gatekeeping step rather than a diagnostic formality.

PSMA stands out as the most mature system, and its success rests on elegant biology. PSMA is a type II transmembrane glycoprotein with a large extracellular domain and ligand-induced internalization, making it highly accessible to small molecules built on the Glu-urea-Lys scaffold. Expression is markedly upregulated in prostate cancer, particularly in high-risk, metastatic, and castration-resistant disease. The pivotal phase III VISION trial demonstrated that lutetium-177-labeled PSMA-617 plus standard care extended median radiographic progression-free survival from 3.4 to 8.7 months and median overall survival from 11.3 to 15.3 months in patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition and taxane chemotherapy. Subsequent real-world studies and meta-analyses have consistently supported both efficacy and an acceptable safety profile, cementing beta-emitter PSMA therapy as established clinical practice rather than an experimental strategy.

Yet the beta emitter is not the end of the story. Beta particles have an intermediate tissue range and low linear energy transfer, producing a cross-fire effect suited to multifocal metastatic disease but potentially inadequate for microscopic residual lesions or tumors with heterogeneous uptake. Actinium-225 offers a different physics: an extremely high linear energy transfer and a micrometer-scale path length that induce clustered, difficult-to-repair DNA damage. In the multicenter retrospective WARMTH Act study of 488 heavily pretreated patients, actinium-225-PSMA therapy yielded a median overall survival of 15.5 months and progression-free survival of 7.9 months, though xerostomia emerged in 68 percent of evaluable patients after the first cycle. The Vienna reviewers position actinium-225 not as a stronger version of lutetium but as a distinct intensification strategy, best reserved for selected refractory scenarios while its dosimetry and sequencing with lutetium remain under active investigation.

Somatosatin receptor targeting, meanwhile, remains the model of stability in neuroendocrine tumors. Among the five SSTR subtypes, SSTR2 predominates in well-differentiated gastroenteropancreatic and midgut neuroendocrine tumors, providing the molecular basis for gallium-68-labeled DOTATATE, DOTATOC, and DOTANOC imaging and for lutetium-177-DOTATATE peptide receptor radionuclide therapy (PRRT), now a standard option for advanced SSTR-positive disease. European practice recommendations designate SSTR PET/CT as the reference-standard imaging modality for candidate selection, with FDG PET/CT complementing it in dedifferentiated or aggressive lesions. Perhaps the most intriguing recent development is the shift from agonists to antagonists. Because antagonists bind a broader range of receptor conformations and more binding sites, they can achieve higher lesion uptake and better tumor-to-background contrast, particularly in liver metastases, as confirmed by a 2025 systematic review and meta-analysis. The antagonist therapeutic lutetium-177-satoreotide tetraxetan has shown high tumor uptake and promising disease control in phase I/II testing, though hematologic toxicity and dosimetric challenges mean it remains an evolving complement rather than a replacement for agonist PRRT.

CXCR4 illustrates a fundamentally different clinical logic. This chemokine receptor drives tumor-cell migration, homing, and marrow invasion, and is associated with aggressiveness and poor prognosis in hematologic malignancies. Imaging with gallium-68-pentixafor PET is especially valuable in B-cell lymphomas and multiple myeloma, sometimes offering higher lesion contrast than FDG PET, and a prospective study in primary central nervous system lymphoma found that a fluorine-18-labeled CXCR4 tracer identified more lesions than FDG PET/CT. Therapy, using lutetium-177 or yttrium-90-labeled pentixather, has deliberately bypassed broad application and instead concentrated on high-intensity bridging or myeloablative treatment before hematopoietic stem-cell transplantation in heavily pretreated lymphoma and myeloma. The marrow toxicity in this setting is not merely an adverse event but part of the therapeutic concept, demanding close coordination between nuclear medicine, hematology, and transplant teams.

FAP targeting extends theranostics beyond tumor cells to the tumor microenvironment itself. FAP is a type II transmembrane serine protease overexpressed on cancer-associated fibroblasts but largely silent in normal adult tissue, making FAPI imaging remarkably effective across stromal-rich solid tumors including pancreatic, biliary, gastrointestinal, and ovarian cancers, sarcomas, and peritoneal metastases. Therapy, however, has lagged imaging for a fundamental pharmacologic reason: early small-molecule FAPI tracers clear rapidly, which produces pristine PET images but limits tumor retention and absorbed dose when labeled with lutetium-177. A 2025 phase II study of lutetium-177-LNC1004 achieved a disease control rate of 46 percent in 28 end-stage metastatic patients with high FAP expression, and a prospective study of the peptide ligand FAP-2286 showed feasibility and safety in FAP-positive gastrointestinal tumors, though benefit was mostly disease stabilization. The competitive frontier now lies in ligand engineering—Evans blue conjugation, albumin-binding modifications, dimerization, and novel scaffolds—all aimed at prolonging intratumoral retention to match the physical half-life of the radionuclide.

Across all four systems, the review identifies recurring translational bottlenecks. Target heterogeneity, both between patients and among lesions within the same patient, can evolve under treatment pressure, as seen when prostate tumors undergo neuroendocrine transdifferentiation and lose PSMA expression. Individualized dosimetry has become clinically decisive rather than academic: patient-specific studies reveal substantial interpatient variation in renal, salivary, lacrimal, and marrow radiation burden even under identical dosing, and the 2025 DUONEN trial showed that per-cycle organ dosimetry can safely guide activity adjustments below cumulative thresholds of 23 Gy for kidneys and 2 Gy for bone marrow. Organ protection is shifting from passive management toward active optimization through ligand design and dosimetry-guided dosing, particularly for the salivary glands that limit alpha-emitter PSMA therapy.

The wider horizon is expanding on two axes simultaneously. New targets including CCK2R, GRPR, and CAIX are entering clinical development, while novel radionuclides such as lead-212, terbium-161, and copper- and lead-based theranostic pairs offer different half-lives, emission profiles, and tissue ranges that change which ligands and lesion types they suit. The first-in-human VIOLET study of terbium-161-PSMA-I&T in metastatic castration-resistant prostate cancer exemplifies this dual expansion within an established target system. The Vienna authors argue that radioligand therapy must ultimately be embedded in multidisciplinary pathways that weigh sequencing against androgen receptor inhibitors, chemotherapy, PARP inhibitors, and immunotherapy, and that integrate supportive care, symptom control, and quality-of-life assessment rather than relying solely on imaging or biochemical endpoints. Their verdict is measured but clear: PSMA and SSTR constitute the proven backbone of nuclear theranostics, while CXCR4 and FAPI point toward a future in which the tumor microenvironment and the marrow niche, not just the tumor cell, become therapeutic targets in their own right.

Subject of Research: Molecular targets in oncologic radionuclide therapy and theranostics

Article Title: Advances in molecular targets for oncologic radionuclide therapy

Article References: Zhang, H., Xue, S., Wen, S., Wang, Z., Li, X., Jia, Y., Hacker, M., & Li, X. (2026). Advances in molecular targets for oncologic radionuclide therapy. Holistic Integrative Oncology, 5(1), Article 77. https://doi.org/10.1007/s44178-026-00293-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00293-6

Keywords: radionuclide therapy, theranostics, PSMA, SSTR, CXCR4, FAPI, lutetium-177, actinium-225, dosimetry, prostate cancer, neuroendocrine tumors, radioligand therapy

The radioligand at the center of the study, [177Lu]Lu-P15-073, is a lutetium-177-labeled bisphosphonate. Bisphosphonates are compounds with a natural affinity for regions of active bone remodeling, where they bind to hydroxyapatite mineral. Because metastatic lesions in bone typically trigger intense local bone turnover, radiolabeled bisphosphonates accumulate preferentially at these sites, allowing the beta-minus radiation emitted by lutetium-177 to irradiate tumor cells embedded in the skeletal niche while sparing most healthy tissue. The companion imaging agent [68Ga]Ga-P15-073, labeled with the positron emitter gallium-68, allows clinicians to visualize where the therapeutic compound will lodge before committing to treatment, a theranostic pairing familiar from the success of prostate-specific membrane antigen-targeted radioligand therapy in prostate cancer.

The study’s authors set out to investigate an underappreciated dimension of this approach. The efficacy of bone-seeking radiopharmaceuticals, they argued, depends not only on radiation dosimetry, the traditional calculus of how much dose reaches tumor versus healthy organs, but also on the biological stability of the skeletal microenvironment itself. High-dose beta irradiation from [177Lu]Lu-P15-073, they hypothesized, might damage the bone niche in ways that inadvertently promote cancer progression. To test this, the team built an intratibial xenograft model, implanting human A549 lung adenocarcinoma cells directly into the tibia of experimental animals, and paired the model with quantitative proteomics to map, molecule by molecule, how the bone microenvironment responded to the therapeutic radiation.

The results revealed a sobering pattern. Although the radioligand showed sustained retention in the implanted bone tumors, confirming that the agent effectively targets skeletal lesions, animals receiving radioligand monotherapy fared worse than expected. At the experimental endpoint, the monotherapy group carried a higher pulmonary metastatic burden, meaning more lung cancer colonies had taken root in the lungs. Proteomic and structural analyses pointed toward a mechanism: the therapeutic radiation was associated with osteoclastogenesis, the formation and activation of the bone-resorbing cells that dismantle skeletal matrix, and with lipid-metabolic reprogramming in the bone microenvironment, marked by upregulation of the proteins FABP4 and PLIN1. These molecular shifts were accompanied by cortical bone degradation and, ultimately, by increased seeding of metastases in the lungs.

The lipid biology here is particularly intriguing. FABP4, a fatty acid-binding protein, and PLIN1, which coats intracellular lipid droplets, are classic markers of adipocyte differentiation and lipid accumulation. Their upregulation suggests that radiation reshaped the metabolic character of the bone niche, potentially enriching it with lipid-laden cells of the sort known to provide metabolic support to disseminated tumor cells. In the vicious cycle of bone metastasis, tumor-driven and treatment-driven osteolysis releases growth factors stored in bone matrix, fueling tumor growth further, while the resorbed architecture weakens the skeleton and opens routes for cancer cells to escape into circulation and colonize distant organs such as the lungs.

Having identified the mechanism, the researchers tested a mechanistically driven countermeasure: concurrent inhibition of RANKL, the receptor activator of nuclear factor kappa-B ligand. RANKL is the master signaling molecule that drives osteoclast differentiation and activation, and blocking it is already a clinically validated strategy for protecting bone in patients with metastatic disease. The anti-RANKL antibody denosumab is widely used to prevent skeletal-related events in cancer care. In the preclinical experiments, adding RANKL blockade to the radioligand regimen attenuated the radiation-associated osteoclastogenesis, blunted the lipid-metabolic reprogramming, and preserved skeletal integrity, effectively holding the bone niche together while the radiation attacked the tumor.

The impact on clinically meaningful outcomes was substantial. Pulmonary metastasis developed in only 25 percent of animals receiving the combination, compared with 87.5 percent of those treated with radioligand monotherapy and 75 percent of controls. Median survival also increased significantly, exceeding 50 days in the combination group versus 37.5 days in the monotherapy group, a difference the authors report as statistically significant with a P value below 0.01. In a disease context where bone metastases of lung cancer carry a bleak prognosis and few effective options, a treatment combination that both keeps the skeleton intact and curbs distant spread represents an unusually encouraging preclinical signal.

The study also extended into the clinic, albeit in a preliminary way. The team analyzed imaging data and early outcomes from a registered cohort of patients with bone-metastatic lung cancer, drawing on the clinical trial of lutetium-177-labeled phosphonates registered as ChiCTR2300077313 in November 2023. Translational morphological imaging showed heterogeneous remodeling patterns across treated lesions: a representative lesion in a patient exposed to denosumab, the RANKL inhibitor, showed signs of osteogenic repair, with new bone formation healing the damaged architecture, while a representative lesion treated with radioligand alone displayed progressive osteolysis, the characteristic moth-eaten destruction of bone. Although these clinical observations are preliminary and the human cohort was small, they mirror the biology observed in the animal models and lend translational weight to the combination hypothesis.

The authors are careful to frame their conclusions as associations and rationale rather than proof. Radiation-driven osteolysis and lipid reprogramming, they write, may represent factors that limit the efficacy of bone-targeted monotherapy, and concurrent RANKL inhibition may help stabilize the skeletal microenvironment and reduce the pulmonary metastatic burden observed in this model. The findings, they conclude, provide a preclinical rationale for further evaluation of RANKL inhibition alongside bone-seeking radioligands. Such measured language is appropriate for a study whose human component is exploratory, and the registered trial will be the venue in which the strategy faces the rigor of prospective clinical testing.

Nevertheless, the conceptual contribution of the work may prove as important as any single result. It challenges the field to think beyond dosimetry when designing bone-targeted radiopharmaceuticals, and to treat the bone microenvironment not as passive scenery but as an active, modifiable participant in treatment response. If radiation can inadvertently remodel the niche into a metastasis-promoting state, then protecting that niche may be as essential as delivering the dose itself. For patients with lung cancer that has invaded the skeleton, where the disease is incurable and skeletal complications compound an already difficult prognosis, a rational pairing of a bone-seeking radioligand with an osteoclast-blocking antibody offers a genuine path forward, and one that leverages drugs already on pharmacy shelves.

Subject of Research: Combining RANKL inhibition with bone-targeted radioligand therapy for lung cancer bone metastases

Article Title: RANKL inhibition potentiates bone-targeted radioligand therapy in lung cancer metastases: a translational study

Article References: Zhao, R., Deng, Y., Liang, W., Xu, M., Lv, J., Zhang, J., Wang, J., Liang, W., Zhou, C., Yu, P., Li, J., Zhu, L., Kung, H. F., & Wang, X. (2026). RANKL inhibition potentiates bone-targeted radioligand therapy in lung cancer metastases: a translational study. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09021-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09021-0

Keywords: radioligand therapy, lung cancer, bone metastases, RANKL inhibition, lutetium-177, bisphosphonates, osteoclastogenesis, denosumab, bone microenvironment, lipid metabolic reprogramming, FABP4, theranostics

The research, published in the European Journal of Nuclear Medicine and Molecular Imaging, examined whether body composition measured on routine CT scans could predict which patients would experience early progression after PRRT. The idea rests on a growing body of evidence in oncology: it is not merely how much muscle a patient carries, but the quality of that muscle, that shapes outcomes across a striking range of cancers. Previous studies have linked fatty infiltration of muscle, a condition called myosteatosis, to poorer survival after pancreatic surgery, worse responses to chemoembolization in liver cancer, and altered activity of immunotherapies in metastatic melanoma.

Myosteatosis is best understood as muscle that has been quietly invaded by fat at the microscopic level. On a CT scan, healthy skeletal muscle appears relatively dark because it contains abundant water-dense contractile tissue. When fat infiltrates the muscle fibers, the tissue’s average density drops, which radiologists measure in Hounsfield units on the standard gray-scale of CT imaging. Crucially, researchers can extract these measurements from virtually any abdominal CT, including the CT component of a PET/CT scan that every PRRT patient already receives, simply by analyzing a slice at the level of the third and fourth lumbar vertebrae, where the psoas muscles anchor the spine.

The Munich team, led by first authors Elma Dema and Christian Dascalescu under the senior guidance of Rudolf Werner and Sophie Siegmund, screened 321 consecutive patients who underwent PRRT for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Complete imaging and follow-up data were available for 301 of them. Using BMI-adjusted cut-offs for psoas muscle attenuation, the investigators defined which patients had myosteatosis at baseline, before a single radioactive dose had been administered. Their primary endpoint was deliberately stringent: early progression as seen on somatostatin receptor-targeted PET imaging after up to four consecutive treatment cycles, dichotomized as progressive disease versus disease control.

The headline result was, in one sense, a negative one. Traditional quantity-based measures of body composition, including skeletal muscle area and related indices that simply quantify how much muscle tissue surrounds the spine, showed no association whatsoever with early progression. Muscle bulk alone, it seems, tells clinicians nothing useful about whether a neuroendocrine tumor will shrug off PRRT within the first treatment window. This finding matters because muscle quantity is still the most commonly reported body composition parameter in oncology literature, often treated as a stand-in for overall nutritional reserve.

The quality-based measure told a more intriguing story. Only eight of the 301 patients, a mere 2.7 percent, met the criteria for baseline myosteatosis, yet those eight appeared to fare strikingly worse. In univariable analysis, myosteatosis was associated with roughly an eight-fold increase in the odds of early PET-based progression, with an odds ratio of 7.8 and a 95 percent confidence interval running from 1.74 to 34.78, yielding a nominal p-value of 0.0073. In a separately specified model adjusted for baseline clinical characteristics, the association held steady at an odds ratio of 8.1. But here the statistical plot thickens considerably.

When the researchers applied the Benjamini-Hochberg procedure, a standard correction that controls the false discovery rate when multiple hypotheses are tested simultaneously, the p-value drifted to 0.1073, crossing above the conventional significance threshold. The association was also attenuated when the number of completed PRRT cycles was added as a post-baseline treatment exposure variable, landing at an odds ratio of 5.7 with a confidence interval that narrowly grazed 1.0 and a p-value of 0.0538, just shy of the 0.05 benchmark. With only eight affected patients, the confidence intervals around these estimates were wide, which is the statistical signature of a hypothesis that cannot yet be called a finding.

The authors are admirably blunt about this limitation. They conclude that the results should be regarded as exploratory and hypothesis-generating, and that they do not establish any clinical utility for myosteatosis in individual risk stratification. In plain terms, no one should yet order a CT-based muscle analysis to decide who gets PRRT or how closely they should be monitored. The study also reveals a practical puzzle: myosteatosis was far rarer in this cohort than the 30 to 50 percent prevalence reported in some other cancer populations treated with PRRT, suggesting that the BMI-adjusted thresholds used here may flag only the most severe cases, or that neuroendocrine tumor patients differ fundamentally in their metabolic profiles.

Why might fat-infiltrated muscle and treatment resistance be connected at all? The mechanisms remain speculative, but several plausible pathways have been described in the wider literature. Myosteatosis is considered a marker of systemic metabolic derangement, reflecting chronic inflammation, insulin resistance, and altered mitochondrial function within muscle tissue. These same processes could plausibly influence tumor biology, modulate the delivery of radiopharmaceuticals, or shape how the body tolerates and responds to radiation. Some researchers have even proposed myosteatosis as an early and targetable biomarker of cancer prognosis, a measurable vulnerability that nutritional or exercise interventions might one day reverse before treatment begins.

For the field of nuclear medicine, the study is a careful lesson in statistical humility and a genuine invitation to dig deeper. Early progression after PRRT occurs in roughly 8 percent of patients, and identifying this minority before therapy would allow clinicians to consider intensified surveillance, alternative sequencing, or combination approaches for those at highest risk. The Munich data suggest that the search should move beyond how much muscle a patient has and toward the finer architecture of that muscle, ideally with larger, prospective cohorts and standardized measurement protocols. Until then, the radioactive missile remains a remarkably effective weapon, even if the secrets of the rare patients it fails are still written, faintly, in their own flesh.

Subject of Research: Association between CT-based body composition and early progression after peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors

Article Title: Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis

Article References: Dema, E., Dascalescu, C., Holzgreve, A., Cyran, C. C., Widjaja, L., Gildehaus, F. J., Herr, F. L., Spitzweg, C., Auernhammer, C. J., Ingrisch, M., Brendel, M., Ricke, J., Werner, R. A., & Siegmund, S. C. (2026). Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08182-w

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08182-w

Keywords: PRRT, neuroendocrine tumors, body composition, myosteatosis, lutetium-177, PET/CT, sarcopenia, radiomics, nuclear medicine, cachexia, psoas muscle, tumor progression